Search Results - HERREM, Christopher J

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma

    Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma by HERREM, Christopher J, TATSUMI, Tomohide, STORKUS, Walter J, OLSON, Kathleen S, SHIRAI, Keisuke, FINKE, James H, BUKOWSKI, Ronald M, MING ZHOU, RICHMOND, Amy L, DERWEESH, Ithaar, KINCH, Michael S

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma

    Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma by TATSUMI, Tomohide, HERREM, Christopher J, OLSON, Walter C, FINKE, James H, BUKOWSKI, Ronald M, KINCH, Michael S, RANIERI, Elena, STORKUS, Walter J

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists

    Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists by Wesa, Amy K, Herrem, Christopher J, Mandic, Maja, Taylor, Jennifer L, Vasquez, Cecilia, Kawabe, Mayumi, Tatsumi, Tomohide, Leibowitz, Michael S, Finke, James H, Bukowski, Ronald M, Bruckheimer, Elizabeth, Kinch, Michael S, Storkus, Walter J

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Enhancement in Specific CD8+ T cell Recognition of EphA2+ Tumors In Vitro and In Vivo After Treatment with Ligand Agonists1

    Enhancement in Specific CD8+ T cell Recognition of EphA2+ Tumors In Vitro and In Vivo After Treatment with Ligand Agonists1 by Wesa, Amy K., Herrem, Christopher J., Mandic, Maja, Taylor, Jennifer L., Vasquez, Cecilia, Kawabe, Mayumi, Tatsumi, Tomohide, Leibowitz, Michael S., Finke, James H., Bukowski, Ronald M., Bruckheimer, Elizabeth, Kinch, Michael S., Storkus, Walter J.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: